OCTAVE Induction | Xeljanz® (tofacitinib citrate)

This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Log Out

Single Link

Dropdown

Label

Link

Linked Dropdown

Label

Link

Mega Menu

Heading

Example of description text sitting alongside header

Label

Link

Label

Link

Label

Link

Linked Mega Menu

Heading

Example of description text sitting alongside header

Label

Link

Label

Link

Label

Link

EN - English

Select a language

Languages

EN - English

FR - Françias

Log Out

Single Link

Dropdown

Label

Link

Linked Dropdown

Label

Link

Mega Menu

Heading

Example of description text sitting alongside header

Label

Link

Label

Link

Label

Link

Linked Mega Menu

Heading

Example of description text sitting alongside header

Label

Link

Label

Link

Label

Link

EN - English

Select a language

Languages

EN - English

FR - Françias

Log Out

Pfizer Medicines

Therapy Areas

Explore Content

Events

Videos

Materials

Featured Articles

Let’s Connect

Supply

Alliance Healthcare

Off-contract claims

Adverse event reporting can be found at the bottom of the page

About

How XELJANZ works

XELJANZ in Action

Cytokines

Signalling Pathways

Dosing

Dosing in RA

Dosing in UC

Dosing in PsA

Dosing in pJIA and jPsA

Dosing in AS

Special Warnings & Precautions

Efficacy & Safety

Safety & Tolerability

Oral Surveillance

Adverse Events

Clinical Efficacy RA

ORAL Strategy Study Design

ORAL Strategy Efficacy Results

ORAL Strategy Safety Outcomes

Clinical Efficacy UC

OCTAVE Study Design

OCTAVE Sub Groups

OCTAVE Induction

OCTAVE Sustain

Post-hoc Analyses

Clinical Efficacy PsA

OPAL Broaden & Beyond

Clinical Efficacy pJIA and jPsA

JIA-1 Study Design

JIA-1 Efficacy Results

JIA-1 Safety Outcomes

Clinical Efficacy AS

ASAS20/40 Data

ASDAS(CRP) Data

Real World Evidence

Why Real-World Data?

Key Characteristics of RCTs & RWE

Key Strengths & Limitations

STAR-RA

Malignancy Study Design

Malignancy Risk Outcomes

CV Risk Study Design

CV Risk Outcomes

SCQM-RA

Study Design

Study Outcomes

CorEvitas RA

Safety Study Design

Efficacy Study Design

Outcomes

UC RWE

TOUR Registry (US)

Honap Study (UK)

Supporting Resources

Materials

Videos

GRAPPA Guidelines

Expert Opinions

XELJANZ® (tofacitinib citrate) Prescribing Information and Maxtrex (methotrexate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.

Tofacitinib should only be used if no suitable treatment alternatives are available in patients:

65 years of age and older;
patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers);
patients with malignancy risk factors (e.g. current malignancy or history of malignancy)

These risks are considered class effects and relevant across all approved indications of JAKi in inflammatory and dermatologic diseases.

OCTAVE Induction

Adapted from Sandborn WJ et al. 2017.¹ Full analysis set - non-responder imputation.

Remission in OCTAVE Induction 1 and 2 was defined as a Total Mayo score of ≤2, with no subscore >1 and a rectal bleeding subscore of 0.

Central reading of endoscopic findings was used for eligibility and primary efficacy endpoint analyses.¹ In OCTAVE Induction 1, patients had a mean Total Mayo score of 9 at baseline (n=598). 51% had previously failed TNFi; 75% corticosteroids; 74% immunosuppressant therapy. Previous treatment failure was determined by the investigator.¹In OCTAVE Induction 2, patients had a mean Total Mayo score of 9 at baseline (n=541). 52% had previously failed TNFi; 71% corticosteroids; 69% immunosuppressant therapy. Previous treatment failure was determined by the investigator.¹BID=twice daily; TNFi=tumour necrosis factor inhibitor.

Adapted from Sandborn WJ et al. 2017.¹ Full analysis set - non-responder imputation.

Mucosal healing was defined as improvement in the endoscopic appearance of the mucosa to subscore 0 or 1.¹

In OCTAVE Induction 1, patients had a mean Total Mayo score of 9 at baseline (n=598). 51% had previously failed TNFi; 75% corticosteroids ; 74% immunosuppressant therapy. Previous treatment failure was determined by the investigator.¹In OCTAVE Induction 2, patients had a mean Total Mayo score of 9 at baseline (n=541). 52% had previously failed TNFi; 71% corticosteroids; 69% immunosuppressant therapy. Previous treatment failure was determined by the investigator.¹BID=twice daily

Clinical response after 8-week induction treatment with XELJANZ^1,2

The rates of clinical response at 8 weeks were significantly higher with XELJANZ 10 mg BID vs. placebo¹

Patients were eligible to enter the OCTAVE Sustain trial if they had a clinical response during OCTAVE Induction 1 or 2

Adapted from Sandborn WJ et al. 2017.¹ Full analysis set - non-responder imputation.

Clinical response was defined as a decrease from baseline in the Total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.¹

Dosing in UC

Visit page

References

Sandborn WJ et al. N Engl J Med 2017; 376(18): 1723–1736

XELJANZ (tofacitinib citrate) Summary of Product Characteristics.

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

PP-XEL-GBR-3947. October 2022

Clinical Efficacy UC

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. October 2020

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search

for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

This website is brought to you by Pfizer Limited, a company registered in England

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024

You are now leaving PfizerPro

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd.

Pfizer accepts no responsibility for the content or services of the linked site.

PP-PFE-GBR-3858. November 2021

You are now leaving PfizerPro

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd.

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to Pfizer medicines or
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021